P302 Retention on Treatment With Lumiracoxib in Patients With Osteoarthritis

Fleischmann, R.; Tannenbaum, H; Patel, Neelkumar; Notter, Marianne; Sallstig, Peter; Reginster, Jacques

doi:10.1016/s1063-4584(07)60750-x

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the long‐term efficacy and safety of lumiracoxib 100 mg o.d. has been shown in several clinical studies 11,15,16 . Lumiracoxib 100 mg o.d.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week, randomized, double‐blind, parallel‐group study

Bin

Zeng

et al. 2007

APLAR Journal of Rheumatology

View full text Add to dashboard Cite

Aim:The aim of the current study was to assess the efficacy, safety, and tolerability of lumiracoxib 200 mg once daily (o.d.) in relieving osteoarthritis (OA) knee pain in patients in China, Taiwan, and South Korea.Methods: Patients of either sex (aged ≥ 18 years) with symptomatic, primary OA of the knee for ≥ 3 months were eligible for inclusion if they had OA pain intensity of ≥ 40 mm (100 mm visual analogue scale [VAS]) in the target knee joint during the previous 24 h. Patients were required to undergo regular non-steroidal antiinflammatory drug therapy for ≥ 6 weeks. After 3-7 days of screening, patients were randomized (1 : 1) to receive either lumiracoxib 200 mg o.d. or celecoxib 200 mg o.d. The primary efficacy comparison between the study groups was overall OA pain intensity (VAS) in the target knee after 6 weeks of treatment. Results:The mean overall OA pain intensity (VAS) in the target knee after 6 weeks decreased from 60.6 mm to 35.7 mm and 60.5 mm to 36.1 mm in the lumiracoxib and celecoxib groups, respectively. Both study groups showed similar results in terms of improvement in both patient's and physician's global assessment of disease activity and functional health status. The percentage of adverse events (AEs) in the lumiracoxib and celecoxib groups (40.3% and 37.9%, respectively) was similar, as was the proportion of treatment-related AEs (21.0% and 18.2%, respectively). Conclusions: Lumiracoxib 200 mg o.d. provided effective and well-tolerated pain relief similar to that achieved with celecoxib 200 mg o.d. in knee OA patients.

show abstract

“…In addition, the long‐term efficacy and safety of lumiracoxib 100 mg o.d. has been shown in several clinical studies 11,15,16 . Lumiracoxib 100 mg o.d.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week, randomized, double‐blind, parallel‐group study

Bin

Zeng

et al. 2007

APLAR Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…Lumiracoxib is a structurally distinct, selective COX-2 inhibitor for the management of OA and acute pain. Lumiracoxib is effective in treating acute pain conditions such as post-operative dental pain [ 15 ], acute gout [ 16 ], arthroplasty [ 17 ], sprains and strains [ 18 ] and in treating chronic pain associated with OA [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients

Stricker

Krammer

2008

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background: Lumiracoxib is a selective cyclooxygenase-2 inhibitor effective in the treatment of osteoarthritis (OA) with a superior gastrointestinal (GI) safety profile as compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs, ibuprofen and naproxen). This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA. Rofecoxib was withdrawn worldwide due to an associated increased risk of CV events and lumiracoxib has been withdrawn from Australia, Canada, Europe and a few other countries following reports of suspected adverse liver reactions.

show abstract

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

et al. 2011

View full text Add to dashboard Cite

The aim of this 13-week, multicenter, randomized, double-blind, double-dummy, placebo- and positive-internal (celecoxib)-controlled, parallel-group study was to demonstrate the efficacy, safety, and tolerability of lumiracoxib in primary hip osteoarthritis (OA) patients. Eligible patients (n = 1,262; ACR criteria) were randomized (1:1:1) to receive lumiracoxib 100 mg once daily (o.d.) (n = 427), celecoxib 200 mg o.d. (n = 419), or matching placebo o.d. (n = 416) administered orally. The primary objective was to compare lumiracoxib 100 mg o.d. and placebo with respect to three co-primary efficacy variables: the pain subscale of the Western Ontario and McMaster Universities Osteoarthritis Index Likert version 3.1 (WOMAC™ LK 3.1) questionnaire, the function subscale of the WOMAC™ LK 3.1 questionnaire, and patient's global assessment of disease activity (100-mm visual analog scale (VAS)) after 13 weeks of treatment. Of the 1,262 randomized patients, 951 completed the study. All randomized patients were included in the intention-to-treat and safety populations. Lumiracoxib was superior to the placebo (p < 0.001) after 13 weeks for all three co-primary endpoints. By week 13, the patient's global assessment of disease activity (100-mm VAS) improved by 23.3 mm (±SD, 27.83 mm) with lumiracoxib and 13.3 mm (±26.71 mm) with placebo. The WOMAC™ function score decreased by 10.4 (±13.56) with lumiracoxib and 6.8 (±12.55) with placebo. The WOMAC™ pain scores decreased by 3.4 (±4.16) with lumiracoxib and 2.2 (±3.94) with placebo at week 13. Similar results were observed for secondary endpoints: OA pain intensity and WOMAC™ total score. Lumiracoxib was similar to celecoxib for all three co-primary endpoints. All treatments were well tolerated. In conclusion, lumiracoxib is effective in reducing pain and improving function in hip OA patients.

show abstract

P302 Retention on Treatment With Lumiracoxib in Patients With Osteoarthritis

Cited by 3 publications

References 0 publications

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week, randomized, double‐blind, parallel‐group study

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week, randomized, double‐blind, parallel‐group study

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

Contact Info

Product

Resources

About